Published in Biochem Soc Symp on January 01, 2001
The GSK3 hypothesis of Alzheimer's disease. J Neurochem (2007) 3.16
Mechanisms of tau-induced neurodegeneration. Acta Neuropathol (2009) 2.27
Retinoic acid attenuates beta-amyloid deposition and rescues memory deficits in an Alzheimer's disease transgenic mouse model. J Neurosci (2008) 1.30
The role of miR-103 and miR-107 in regulation of CDK5R1 expression and in cellular migration. PLoS One (2011) 1.29
Microglial p38α MAPK is a key regulator of proinflammatory cytokine up-regulation induced by toll-like receptor (TLR) ligands or beta-amyloid (Aβ). J Neuroinflammation (2011) 1.25
Alzheimer neurofibrillary degeneration: significance, etiopathogenesis, therapeutics and prevention. J Cell Mol Med (2007) 1.21
Tau-based treatment strategies in neurodegenerative diseases. Neurotherapeutics (2008) 1.13
The p38 MAP Kinase Family as Regulators of Proinflammatory Cytokine Production in Degenerative Diseases of the CNS. Aging Dis (2010) 1.09
Beta-amyloid1-42 gene transfer model exhibits intraneuronal amyloid, gliosis, tau phosphorylation, and neuronal loss. J Biol Chem (2010) 1.05
Co-localization of glycogen synthase kinase-3 with neurofibrillary tangles and granulovacuolar degeneration in transgenic mice. Am J Pathol (2003) 1.02
Increased tau phosphorylation on mitogen-activated protein kinase consensus sites and cognitive decline in transgenic models for Alzheimer's disease and FTDP-17: evidence for distinct molecular processes underlying tau abnormalities. Mol Cell Biol (2005) 0.94
Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies. Future Med Chem (2011) 0.92
Tau as a therapeutic target for Alzheimer's disease. Curr Alzheimer Res (2011) 0.89
Glycogen synthase kinase-3 inhibitors as potent therapeutic agents for the treatment of Parkinson disease. ACS Chem Neurosci (2012) 0.89
Developing pharmacological therapies for Alzheimer disease. Cell Mol Life Sci (2007) 0.87
The microtubule-associated protein tau is phosphorylated by Syk. Biochim Biophys Acta (2007) 0.86
Therapy for Alzheimer's Disease: How Effective are Current Treatments? Ther Adv Neurol Disord (2009) 0.85
Casein kinase 1 alpha associates with the tau-bearing lesions of inclusion body myositis. Neurosci Lett (2007) 0.84
Increased tau phosphorylation and aggregation in the hippocampus of mice overexpressing corticotropin-releasing factor. J Alzheimers Dis (2015) 0.83
Pro-Apoptotic Kinase Levels in Cerebrospinal Fluid as Potential Future Biomarkers in Alzheimer's Disease. Front Neurol (2015) 0.82
Activation of glycogen synthase kinase 3β ameliorates diabetes-induced kidney injury. J Biol Chem (2014) 0.80
Challenges and new opportunities in the investigation of new drug therapies to treat frontotemporal dementia. Expert Opin Ther Targets (2008) 0.80
Functional Impact of Corticotropin-Releasing Factor Exposure on Tau Phosphorylation and Axon Transport. PLoS One (2016) 0.77
Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology (1996) 12.33
Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet (2013) 9.46
Tau suppression in a neurodegenerative mouse model improves memory function. Science (2005) 8.66
Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat Genet (2000) 6.12
Proteomic analysis of NMDA receptor-adhesion protein signaling complexes. Nat Neurosci (2000) 6.10
Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science (2001) 6.00
Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature (1996) 5.50
Genetic association between intronic polymorphism in presenilin-1 gene and late-onset Alzheimer's disease. Alzheimer's Disease Collaborative Group. Lancet (1996) 5.49
Tauopathy in Drosophila: neurodegeneration without neurofibrillary tangles. Science (2001) 4.25
Association of an extended haplotype in the tau gene with progressive supranuclear palsy. Hum Mol Genet (1999) 4.17
"Operation Berkshire": the international tobacco companies' conspiracy. BMJ (2000) 4.00
Phenotypic correlations in FTDP-17. Neurobiol Aging (2001) 3.96
Jellyfish green fluorescent protein as a reporter for virus infections. Plant J (1995) 3.95
Head injury as a risk factor for Alzheimer's disease: the evidence 10 years on; a partial replication. J Neurol Neurosurg Psychiatry (2003) 3.87
Doctors who smoke. BMJ (1995) 3.26
The ethics of the cash register: taking tobacco research dollars. Tob Control (2001) 3.16
Effects of workplace smoking bans on cigarette consumption. Am J Public Health (1990) 3.08
TNF-alpha converting enzyme (TACE) is inhibited by TIMP-3. FEBS Lett (1998) 3.04
Chasing Ernst L Wynder: 40 years of Philip Morris' efforts to influence a leading scientist. J Epidemiol Community Health (2003) 2.89
Tobacco industry efforts at discrediting scientific knowledge of environmental tobacco smoke: a review of internal industry documents. J Epidemiol Community Health (2001) 2.86
Glycogen synthase kinase-3 induces Alzheimer's disease-like phosphorylation of tau: generation of paired helical filament epitopes and neuronal localisation of the kinase. Neurosci Lett (1992) 2.85
A David and Goliath story: tobacco advertising and self-regulation in Australia. Br Med J (1980) 2.73
Smoking in public places. BMJ (1996) 2.72
Service profiling and outcomes benchmarking using the CORE-OM: toward practice-based evidence in the psychological therapies. Clinical Outcomes in Routine Evaluation-Outcome Measures. J Consult Clin Psychol (2001) 2.72
Evaluation of the Sydney "Quit. For Life" anti-smoking campaign. Part 1. Achievement of intermediate goals. Med J Aust (1986) 2.70
Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir. Antimicrob Agents Chemother (1998) 2.67
Front-loading allied health intervention in the emergency department does not reduce length of stay for admitted older patients. Int J Clin Pract (2013) 2.64
Banning smoking outdoors is seldom ethically justifiable. Tob Control (2000) 2.56
Cancer incidence in the Mexican-American. J Natl Cancer Inst (1975) 2.54
Oral acyclovir in the treatment of acute herpes zoster ophthalmicus. Ophthalmology (1986) 2.53
Susceptibility locus for Alzheimer's disease on chromosome 10. Science (2000) 2.49
The role of doctors in promoting smoking cessation. BMJ (1993) 2.46
Brand preference and advertising recall in adolescent smokers: some implications for health promotion. Am J Public Health (1982) 2.36
Linkage of plasma Abeta42 to a quantitative locus on chromosome 10 in late-onset Alzheimer's disease pedigrees. Science (2000) 2.35
General practitioner anti-smoking programmes: which one? Med J Aust (1990) 2.34
High prevalence of Foxp3 and IL17 in MMR-proficient colorectal carcinomas. Gut (2007) 2.32
Identification and characterization of a novel Bacillus thuringiensis delta-endotoxin entomocidal to coleopteran and lepidopteran larvae. Mol Microbiol (1992) 2.31
"Smoking is a major cause of blindness". Med J Aust (1999) 2.27
A full genome scan for late onset Alzheimer's disease. Hum Mol Genet (1999) 2.26
Estimation of the genetic contribution of presenilin-1 and -2 mutations in a population-based study of presenile Alzheimer disease. Hum Mol Genet (1998) 2.26
A variant of Alzheimer's disease with spastic paraparesis and unusual plaques due to deletion of exon 9 of presenilin 1. Nat Med (1998) 2.20
Metachronous gastric MALT lymphoma and early gastric cancer: is residual lymphoma a risk factor for the development of gastric carcinoma? Ann Oncol (2005) 2.20
The leachability and chemical speciation of selected trace elements in fly ash from coal combustion and refuse incineration. Environ Pollut (1987) 2.19
Proteomics characterization of abundant Golgi membrane proteins. J Biol Chem (2000) 2.13
Minocycline induced autoimmune hepatitis and systemic lupus erythematosus-like syndrome. BMJ (1996) 2.04
Selective inhibition of arachidonate 5-lipoxygenase by novel acetohydroxamic acids: biochemical assessment in vitro and ex vivo. Br J Pharmacol (1988) 2.02
Cumulative conception and livebirth rates after in-vitro fertilisation. Lancet (1992) 2.01
5' splice site mutations in tau associated with the inherited dementia FTDP-17 affect a stem-loop structure that regulates alternative splicing of exon 10. J Biol Chem (1999) 2.00
Open source marketing: Camel cigarette brand marketing in the "Web 2.0" world. Tob Control (2009) 2.00
Proteome-based plasma biomarkers for Alzheimer's disease. Brain (2006) 1.98
Molecular analysis of a resistance-breaking strain of potato virus X. Virology (1992) 1.96
Rating of the lesions in senile dementia of the Alzheimer type: concordance between laboratories. A European multicenter study under the auspices of EURAGE. J Neurol Sci (1990) 1.96
Butyrate oxidation is impaired in the colonic mucosa of sufferers of quiescent ulcerative colitis. Gut (1994) 1.96
Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype. Neurology (2001) 1.95
Health promoting schools and health promotion in schools: two systematic reviews. Health Technol Assess (1999) 1.93
Does amyloid precede paired helical filaments in the senile plaque? A study of 15 cases with graded intellectual status in aging and Alzheimer disease. Neurosci Lett (1988) 1.89
Genetic heterogeneity in familial idiopathic basal ganglia calcification (Fahr disease). Neurology (2004) 1.87
Eyes on the prize: transnational tobacco companies in China 1976-1997. Tob Control (2000) 1.86
An attempt to swindle nature: press anti-immunisation reportage 1993-1997. Aust N Z J Public Health (1998) 1.85
Trapped antihydrogen. Nature (2010) 1.85
Characterization of pathology in transgenic mice over-expressing human genomic and cDNA tau transgenes. Neurobiol Dis (2000) 1.84
Tobacco in the news: an analysis of newspaper coverage of tobacco issues in Australia, 2001. Tob Control (2003) 1.84
The tobacco industry's accounts of refining indirect tobacco advertising in Malaysia. Tob Control (2004) 1.83
Psychological factors in breast cancer. BMJ (1991) 1.82
Stop-smoking clinics: a case for their abandonment. Lancet (1985) 1.81
Alzheimer's paired helical filaments share epitopes with neurofilament side arms. EMBO J (1986) 1.81
Alzheimer's disease-like phosphorylation of the microtubule-associated protein tau by glycogen synthase kinase-3 in transfected mammalian cells. Curr Biol (1994) 1.80
GSK-3beta inhibition reverses axonal transport defects and behavioural phenotypes in Drosophila. Mol Psychiatry (2004) 1.79
Ubiquitin deposits in anterior horn cells in motor neurone disease. Neurosci Lett (1988) 1.77
Ubiquitin-immunoreactive intraneuronal inclusions in amyotrophic lateral sclerosis. Morphology, distribution, and specificity. Brain (1991) 1.74
Antivaccination activists on the world wide web. Arch Dis Child (2002) 1.74
The Fc portion of antibody to yellow fever virus NS1 is a determinant of protection against YF encephalitis in mice. Virology (1993) 1.74
Alpha-2 macroglobulin gene and Alzheimer disease. Nat Genet (1999) 1.73
Differential expression of mycobacterial proteins following phagocytosis by macrophages. Microbiology (2001) 1.71
Children's lives or garden aesthetics? A case study in public health advocacy. Aust J Public Health (1994) 1.70
The epidemiology of endometrial cancer in young women. Br J Cancer (1983) 1.70
New phosphorylation sites identified in hyperphosphorylated tau (paired helical filament-tau) from Alzheimer's disease brain using nanoelectrospray mass spectrometry. J Neurochem (1998) 1.69
Neurofibrillary tangles of Alzheimer's disease: an immunohistochemical study. J Submicrosc Cytol (1985) 1.69
Risk of cutaneous melanoma associated with pigmentation characteristics and freckling: systematic overview of 10 case-control studies. The International Melanoma Analysis Group (IMAGE). Int J Cancer (1995) 1.68
Focus group composition: a comparison between natural and constructed groups. Aust N Z J Public Health (2001) 1.68
Trends in antibiotic prescribing and associated indications in primary care from 1993 to 1997. J Public Health Med (2001) 1.68
A mire of highly subjective and ineffective voluntary guidelines: tobacco industry efforts to thwart tobacco control in Malaysia. Tob Control (2004) 1.67
Chloroquine-induced mania. Br J Psychiatry (1991) 1.66
Risk factors for penile cancer: results of a population-based case-control study in Los Angeles County (United States). Cancer Causes Control (2001) 1.65
A simple rheological method for the in vitro assessment of mucin-polymer bioadhesive bond strength. Pharm Res (1990) 1.64
Clinical significance of antenatal calyceal dilatation detected by ultrasound. Lancet (1990) 1.64
Boswellic acids: novel, specific, nonredox inhibitors of 5-lipoxygenase. J Pharmacol Exp Ther (1992) 1.63
Immunogenicity of peptides derived from a fibronectin-binding protein of S. aureus expressed on two different plant viruses. Vaccine (1999) 1.63
Gone viral? Heard the buzz? A guide for public health practitioners and researchers on how Web 2.0 can subvert advertising restrictions and spread health information. J Epidemiol Community Health (2008) 1.63
Reduction of acetylated alpha-tubulin immunoreactivity in neurofibrillary tangle-bearing neurons in Alzheimer's disease. J Neuropathol Exp Neurol (1996) 1.62
Assembly and movement of a plant virus carrying a green fluorescent protein overcoat. Proc Natl Acad Sci U S A (1996) 1.62
Study of a Swiss dopa-responsive dystonia family with a deletion in GCH1: redefining DYT14 as DYT5. Neurology (2007) 1.62
Overexpression of heat-shock proteins reduces survival of Mycobacterium tuberculosis in the chronic phase of infection. Nat Med (2001) 1.61
Apolipoprotein E: non-cognitive symptoms and cognitive decline in late onset Alzheimer's disease. J Neurol Neurosurg Psychiatry (1996) 1.60